Tiagabine treatment is associated with neurochemical, immune and behavioural alterations in the olfactory bulbectomized rat model of depression
Language English Country Germany Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
18311685
DOI
10.1055/s-2007-993212
Knihovny.cz E-resources
- MeSH
- Olfactory Bulb physiology MeSH
- Immunity, Cellular drug effects MeSH
- Behavior, Animal drug effects MeSH
- Depression psychology MeSH
- Phagocytosis drug effects MeSH
- GABA Agonists pharmacology MeSH
- Corticosterone blood MeSH
- Rats MeSH
- Nipecotic Acids pharmacology MeSH
- Leukocytes drug effects immunology MeSH
- Luminescence MeSH
- Brain Chemistry drug effects MeSH
- Neurotransmitter Agents blood MeSH
- Neutrophils MeSH
- Leukocyte Count MeSH
- Motor Activity drug effects MeSH
- Rats, Wistar MeSH
- Stress, Psychological blood MeSH
- Tiagabine MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- GABA Agonists MeSH
- Corticosterone MeSH
- Nipecotic Acids MeSH
- Neurotransmitter Agents MeSH
- Tiagabine MeSH
INTRODUCTION: Affective disorders are often associated with immune and neuroendocrine disturbances. However, little information on the modulatory effects of antiepileptics on endocrine and immune functions is available. Some novel antiepileptics, including tiagabine, are considered as potential antidepressants. METHODS: We investigated the influence of tiagabine on stress hormone release, cellular immune function and behaviour in rats following olfactory bulbectomy (OB), a well-recognized animal model of depression. RESULTS: Hyperlocomotion in the open field, typical for the OB rodents, was attenuated by repeated treatment with tiagabine (12 mg/kg/day) in a similar fashion to standard antidepressants. OB led to significantly decreased lymphocyte and increased neutrophil counts, and suppressed leukocyte phagocytosis. The OB-induced changes in leukocyte differential counts were not found in the tiagabine-treated group. The OB-induced reduction in plasma noradrenaline levels was normalized following tiagabine treatment. DISCUSSION: The present data bring further evidence on the antidepressant-like action of tiagabine and encourage further research on its use in the treatment of affective disorders. The observed changes in immune and endocrine functions may contribute to its mood stabilizing effect.
References provided by Crossref.org